[Today's focus]

Yuanda Pharmaceutical (00512.HK) subsidiary plans to further acquire 63% of Chongqing Doptai Pharmaceutical Technology's shares for 440 million yuan

Yuanda Pharmaceutical (00512.HK) announced that previously, Xi'an Beilin Pharmaceutical Co., Ltd., a subsidiary of the group, signed an equity investment agreement with Chongqing Doptech Pharmaceutical Co., Ltd. (Doptech Pharmaceutical). According to this, Xi'an Beilin will acquire 27% of Chongqing Doptech Pharmaceutical Technology Co., Ltd.'s shares for no more than RMB 189.54 million after meeting the relevant conditions agreed in the investment agreement.

On January 15, 2024, the buyer and seller reached a second acquisition agreement. The seller agreed to further sell under conditions, and the buyer agreed to further acquire 63% of the target company Chongqing Doputai Pharmaceutical Technology Co., Ltd. for RMB 440 million.

After the completion of the second acquisition agreement, the buyer will hold 90% of the target company's shares.

The acquisition of Doptech Pharmaceutical Technology is a major industrial layout for the Group in the field of cardiovascular and cerebrovascular disease treatment. The field of cardiovascular disease treatment is one of the Group's traditional areas of advantage. Through this acquisition, the Group will enrich the Group's product pipeline, further consolidate and enhance the Group's overall market competitiveness in the field of cardiovascular disease treatment, and provide a driving force for the continuous growth of the Group's performance.

[Important matters]

United Asia Group (00458.HK) enters into a share option agreement to invest in the MASSIMO OSTI brand

Shanghai Industrial Environment (00807.HK) won the bid for the Jiguan Project in Heilongjiang and signed a price increase agreement for Shanghai Qingpu No. 2 Sewage Treatment Plant

[Financial performance]

Johnson Electric Holdings (00179.HK): Revenue of US$2,871 billion in the first nine months increased 7% year over year

Tiangong International (00826.HK): Tiangong Co., Ltd. expects net profit to increase by 128.63% to 157.21% year-on-year in 2023

Jiajin Investment International (00310.HK) Profit Alert: Net loss is expected to increase by no less than 465% year-on-year in 2023

Dragon Resources (01712.HK) Yingxi: Expected net profit of about 4.2 million Australian dollars to 5.5 million Australian dollars in 2023

[Operation Data]

China Metallurgical (01618.HK) signed a new contract amount of 1,424.78 billion yuan in 2023, up 5.9% year-on-year

Xinhua Insurance (01336.HK)'s cumulative original insurance premium income in 2023 was 165.9 billion yuan

China Eastern Airlines Co., Ltd. (00670.HK) passenger turnover increased 260.38% year-on-year in December

China Southern Airlines Co., Ltd. (01055.HK): Passenger capacity investment increased 149.76% year on year in December, passenger turnover increased 197.81% year on year

Yida China (03639.HK): 2023 contract sales amount is about 1,385 billion yuan

[Pharmaceutical Innovation]

China Medical Group (08225.HK): CHG China Medical Group affiliates reached clinical research and promotion cooperation agreements with Yueyang Xinhuada Pharmaceutical and Shandong Langnuo Pharmaceutical on children's psychosocial treatment drugs

Fosun Pharmaceuticals (02196.HK) Holding Subsidiary Receives Clinical Trial Approval for XH-S004 Tablets

CSPC Group (01093.HK): The bispecific fusion protein drug JMT106 was approved for clinical trials in the US

Cansino Biotech (06185.HK): Recombinant Polio Vaccine Starts Phase I Clinical Trials in Australia and Enrollment of the First Subjects

Kang Feng Bio-B (06922.HK): The one-time use of a frozen probe in the cryoadhesion treatment system obtained approval from the State Drug Administration

[Acquisition and sale]

Huiying Holdings (00821.HK) sold a total of 54.54 million shares of China Nuclear Energy

China Childcare Network (01736.HK) plans to sell all shares in Nanjing Wanhui Information Technology for 19.09 million yuan

[Equity Incentives]

China Biopharmaceutical (01177.HK): Purchase of 3.5 million shares under the Restricted Share Award Program

Tianrunyun (02167.HK) grants 498,500 restricted share units

[Issuance of additional shares]

Beijing Capital Finance International (01468.HK) plans to allocate 900 million shares at a discount of approximately 11.89% to raise HK$180 million net

[Repurchase Cancellation]

Tencent Holdings (00700.HK) spent HK$500 million to buy back 1.73 million shares on January 15

Meituan-W (03690.HK) spent HK$400 million to buy back 5.31 million shares on January 15

Ganfeng Lithium (01772.HK) spent 297 million yuan to buy back 7.167 million shares on January 15

AIA (01299.HK) spent HK$135 million to repurchase 2,082,400 shares on January 15

Xiaomi Group-W (01810.HK) spent HK$49.64 million to buy back 3.5 million shares on January 15

China Mobile (00941.HK) spent HK$48.36,000 to buy back 738,000 shares on January 15

Kuaishou-W (01024.HK) spent HK$39.97 million to buy back 854,000 shares on January 15

CIMC Group (02039.HK) spent 34.89 million yuan to buy back 4.186 million shares on January 15

Prudential (02378.HK) spent £4.8912 million to buy back 590,000 shares on January 12

ESR (01821.HK) spent HK$16.22 million to repurchase 1.5 million shares on January 15

China Software International (00354.HK) spent HK$15.923,700 to buy back 3 million shares on January 15

COSCO Marine Holdings (01919.HK) spent HK$15.5566 million to repurchase 1.92 million shares on January 15

Jinshan Software (03888.HK) spent HK$9.993 million to buy back 459,000 shares on January 15

Times Electric (03898.HK) spent HK$7.6026 million to buy back 355,300 shares on January 15

Haier Smart Home (06690.HK) spent 6.926 million yuan to buy back 320,000 A shares on January 15

Greentown Services (02869.HK) spent HK$6.4462 million to repurchase 2.3 million shares on January 15

Deutsche Bank World (02418.HK) spent HK$5.76 million to repurchase 2.898 million shares on January 15

Conch Cement (00914.HK) spent 4.8073 million yuan to buy back 212,200 A shares on January 15

Yum China (09987.HK) spent HK$4.68 million to buy back 15,500 shares on January 11

China Star Group (00326.HK) spent HK$4.1 million to buy back 5 million shares on January 15

Swire Group A (00019.HK) spent HK$3.646 million to buy back 57,500 shares on January 15

Xiansheng Pharmaceutical (02096.HK) spent HK$3.6253 million to buy back 580,000 shares on January 15

Skyworth Group (00751.HK) spent HK$3.608,600 to buy back 1.04 million shares on January 15

SF Express Tongcheng (09699.HK) spent HK$3 million to buy back 290,000 shares on January 15

Fuzhikang Group (02038.HK) cancelled 14.2 million shares repurchased on January 15